timothy sykes logo
CAPR Stock Craters As FDA Slams Deramiocel Data, Lawsuits Loom Thumbnail
G Google News

CAPR Stock Craters As FDA Slams Deramiocel Data, Lawsuits Loom

JACK KELLOGG•UPDATED JUL. 30, 2026, 7:48 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Capricor Therapeutics Inc. stocks have been trading down by -56.01 percent amid heightened concern over its leading pipeline developments.

Key Takeaways Traders Need To Know

  • FDA advisory briefing on deramiocel said the data fail to provide substantial evidence of effectiveness and flagged an unfavorable benefit–risk profile.
  • Regulators highlighted post-hoc and post-randomization changes to deramiocel’s primary endpoint and broader concerns about data handling and statistics.
  • CAPR collapsed roughly 60–70% on the FDA documents, with shares trading near $7.00 after the shock.
  • Multiple plaintiffs’ firms, including Kehoe, Rosen, Block & Leviton, Levi & Korsinsky, and Howard G. Smith, have launched securities investigations tied to CAPR’s prior deramiocel disclosures.

Candlestick Chart

Live Update At 07:48:07 EDT: On Thursday, July 30, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending down by -56.01%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Capricor Therapeutics Inc. just went from steady biotech story to full-blown volatility play. CAPR spent mid‑July comfortably in the high teens and low $20s, closing at $22.43 on 2026/07/06 and holding near $19–21 through 2026/07/24. Then the FDA briefing documents on deramiocel hit, and the chart broke.

On 2026/07/27, CAPR opened at $5.865 and swung as high as $7.85 before closing at $6.995. By 2026/07/28, it was chopping between $5.67 and $7.22, settling at $6.57. That’s a repricing of more than two‑thirds from prior levels, confirming traders now assign far lower odds to deramiocel’s success.

More Breaking News

Fundamentals show why CAPR is so sensitive. The company runs negative returns on equity around the mid‑50% range and a pretax profit margin near ‑489%, classic clinical‑stage biotech math: heavy R&D, no commercial revenue. The balance sheet does offer a cushion, with roughly $105M in cash and a current ratio of 8.4, and total debt is tiny versus equity. For traders, that means CAPR is less about bankruptcy risk right now and almost entirely about regulatory and headline risk around deramiocel.

Why Traders Are Watching CAPR Now

CAPR is in the kind of storm that creates both huge opportunity and huge danger for active traders. The latest FDA advisory committee briefing documents on deramiocel, Capricor Therapeutics’ lead cell therapy for Duchenne‑associated cardiomyopathy, were blunt. Regulators said the HOPE‑2 and HOPE‑3 data do not provide substantial evidence of effectiveness and that the overall benefit–risk profile looks unfavorable, given safety concerns.

It did not stop there. FDA staff called out a post‑hoc change to the primary endpoint analysis and post‑randomization tweaks to the statistical plan. They also raised broader worries about data handling and methodology. When Cantor Fitzgerald analysts reportedly described the FDA write‑up as an “ugly picture,” they captured what the tape already knew: CAPR got repriced in minutes.

After those documents, CAPR shares plunged roughly 60–70%, with intraday drops around 62–65% and levels near $7.00. Five‑minute premarket candles now show wild swings between about $2.37 and $4.00, underscoring just how emotional the trading has become.

The regulatory hit quickly morphed into legal overhang. Kehoe Law Firm, Rosen Law Firm, Block & Leviton, Levi & Korsinsky, and the Law Offices of Howard G. Smith have all announced securities investigations tied to Capricor Therapeutics’ prior messaging on deramiocel’s efficacy data and regulatory feedback. For CAPR, that means any bounce now trades against not only FDA skepticism but also the risk of class actions and discovery.

For momentum traders, this setup is textbook: a former high‑flier, a binary catalyst gone wrong, and volume exploding as CAPR searches for a new equilibrium.

Conclusion

CAPR has become a case study in why biotech trading is not for the faint of heart. Capricor Therapeutics relied heavily on deramiocel as its value engine, and the FDA has now questioned the core of that engine — the evidence of benefit, the data integrity, and even the way trial endpoints were changed after randomization. The market response was brutal but rational: CAPR went from the low $20s to single digits in a matter of days.

Layered on top of that, a wave of securities‑law investigations from firms like Kehoe, Rosen, Block & Leviton, Levi & Korsinsky, and Howard G. Smith adds another risk vector. Even if CAPR stabilizes around cash value, traders have to factor in legal costs, management distraction, and the chance that more damaging disclosures surface.

For short‑term traders, CAPR is likely to remain a rapid‑fire vehicle, with every new FDA comment or lawsuit headline sparking sharp moves. For those studying the chart, the key is to respect both the range and the risk. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.” That mindset is crucial with names like CAPR, where chasing spikes without a clear plan can be especially punishing.

Tim Sykes always drills the same lesson: “The market doesn’t care about your hopes — it cares about catalysts and risk. Cut losses quickly and let the setup, not your emotions, dictate your trade.” CAPR is exactly that kind of educational tape — a live reminder that in speculative biotech, due diligence on data and risk is just as important as spotting the next big runner.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”